AUTHORS
Nicolò Danesin, MD, Alberto Guijosa, MD2, Tarek Mouhieddine, MD3, Camille Edwards, MD4, Steven Treon, MD, PhD5, Shayna Sarosiek, MD6, Jorge J Castillo, MD7
AFFILIATIONS
1 Bing Center for Waldenstrom Macroglobulinemia, Dana Farber Cancer Institute, Boston, Massachusetts, United States, Hematology Unit, Padova, Padova, Italy
2 Bing Center for Waldenstrom Macroglobulinemia, Dana Farber Cancer Institute, Boston, Massachusetts, United States
3 Bing Center for Waldenstrom Macroglobulinemia, Dana Farber Cancer Institute, Boston, Massachusetts, United States
4 Bing Center for Waldenstrom Macroglobulinemia, Dana Farber Cancer Institute, Boston, Massachusetts, United States
5 Bing Center for Waldenstrom Macroglobulinemia, Dana Farber Cancer Institute, Boston, Massachusetts, United States
6 Bing Center for Waldenstrom Macroglobulinemia, Dana Farber Cancer Institute, Boston, Massachusetts, United States
7 Bing Center for Waldenstrom Macroglobulinemia, Dana Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Background: Ibrutinib represents the first Bruton tyrosine kinase inhibitor (BTKi) approved for Waldenstrom Macroglobulinemia (WM). Its long-term survival benefits have been described despite the unique kind of toxicities. The randomized trial (ASPEN) showed an improved adverse event (AE) profile of zanubrutinib as compared to ibrutinib without significant impact on survival outcomes. A trial sub analysis on 47 patients who transitioned from ibrutinib to zanubrutinib demonstrated 59% overall improvement in the AEs. Additional off trial data are not reported.
Methods: We retrospectively analyzed WM patients on first line or relapsed therapy who switched treatment from ibrutinib to zanubrutinib due to AEs and evaluated at the Dana-Farber Cancer Institute between Jan 2012 and May 2026. Baseline characteristics were collected at the time of BTKi initiation. AEs documented during ibrutinib exposure were classified from clinical records as improved, unchanged, or resolved after switching. IgM trend was represented using median values at 4 different timepoints. Progression free survival (PFS) and overall survival (OS) estimates were represented with Kaplan-Meier and compared with log-rank test to a cohort of ibrutinib-only exposed patients. A 1:1 nearest-neighbor covariate matching without replacement was performed using baseline age (±5 years), IgM level (±1500 mg/dL), hemoglobin (±1.5 g/dL), overall time on BTKi (±24 months), prior lines of therapy (exact), MYD88 mutation status (exact). Progression or death on ibrutinib for the matched cohort or on zanubrutinib for the switching cohort respectively were considered as PFS events.
Results: 13 out of 100 cases switching to zanubrutinib were excluded (6 for missing data, 5 for IgM progression and 2 for BNS progression) finally including 87 patients. Median follow-up from BTK initiation was 77.8 months (95% CI 63.5–95.1). Median time to switching was 35.7 months (IC 95% 27.2–48.9) and from switching to last follow up was 38.6 months (95% CI 29.2–45.6). Median age was 68 years (61-74) with 47% of cases previously treated and 26% who had prior ibrutinib dose reduction. MYD88, CXCR4, and TP53 mutation frequencies were 97%, 41%, and 17%, respectively. The primary AE leading to switching was arrythmia (33%), followed by gastrointestinal symptoms (15%), mucocutaneous manifestations (11%), hypertension (9%), musculoskeletal symptoms (7%), constitutional symptoms (6%), bleeding (2%), infections (2%), and other (14%). Two concomitant AEs occurred in 25% of patients while 6% experienced 3 or more AEs. Overall, 73 out of 87 were evaluable for a reassessment of the AEs after switching from ibrutinib to zanubrutinib. Notably, 81% of cases had an improvement or resolution of the main AE after switching. The highest rates of improvement/resolution were seen in patients with arrythmia (82%), gastrointestinal symptoms (92%), mucocutaneous manifestations (90%), bleeding (100%) or hypertension (75%), while the lowest was reported for musculoskeletal AEs (50%) and infections (50%). There were no significant differences in baseline features between those with unchanged and improved/resolved AEs, although there was a trend towards higher prevalence of CXCR4 mutation for those with no change in AEs (67% vs 29%, p = 0.055). At last follow up 93% of patients were still on active treatment with zanubrutinib. There was a continuous reduction in serum IgM levels after ibrutinib initiation (median IgM 3094 to 656 mg/dL) which was maintained after switching (1074 mg/dL) and continued at the last response assessment (502 mg/dL). There was no significant difference in PFS when comparing those who transitioned to zanubrutinib to a matched ibrutinib-only exposed cases [132 months (IC 95% 132-NR) vs 114 months (IC 95% 105-NR), HR 1.53 p = 0.172]. Similarly, OS analysis showed no difference.
Conclusions: To our knowledge this is the largest described cohort of WM patients switching from ibrutinib to zanubrutinib. This transition was associated with meaningful improvement in tolerability, especially with respect to cardiovascular, gastrointestinal and mucocutaneous AEs. Serum IgM levels continued on a downward trajectory even after transitioning to Zanubrutinib. Despite the retrospective design, efficacy data support the preservation of PFS and OS after switching in a long-term follow up, highlighting the importance of a proactive switching strategy in ibrutinib-intolerant WM patients.
DISCLOSURES
Nicolò Danesin, MD: No relevant conflicts of interest to declare.